AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ: CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful launch and commercialization of their diagnostic tests in uveal and cutaneous melanoma.

Related Keywords

Castle Biosciences ,David Nikodem ,Dan Bradbury ,Mental Health ,Member Of Biobrit ,York State Department Of Health ,Equillium Inc ,Life Sciences Consulting ,Investment Firm ,Amylin Pharmaceuticals ,Altheadx Inc ,Altheadx Board ,Managing Member ,Executive Chairman ,San Diego Based ,New York State Department ,Randomized Controlled ,Derek Maetzold ,Depression And Anxiety ,Ltheadx ,Paetzold ,Board Of Directors ,Rançois Ferré ,Commercial Stage ,Encysive Pharmaceuticals ,கோட்டை உயிர் அறிவியல் ,டான் பிராட்பரி ,மன ஆரோக்கியம் ,யார்க் நிலை துறை ஆஃப் ஆரோக்கியம் ,வாழ்க்கை அறிவியல் ஆலோசனை ,முதலீடு நிறுவனம் ,நிர்வகித்தல் உறுப்பினர் ,நிர்வாகி தலைவர் ,சான் டியாகோ அடிப்படையிலானது ,புதியது யார்க் நிலை துறை ,